Movement Alert｜AKESO Rises 4.26% in Regular Trading, ESMO Conference Catalyzes Innovative Drug Valuation

Market Focus

Yesterday

On October 9, AKESO rose 4.26% in regular trading, trading at HK$110.0/share, with Turnover of HK$892 million.

The ESMO 2026 Annual Meeting will be held from October 23 to 27. Chinese innovative drug research accounts for over 30% of Late-Breaking Abstracts (LBA), among which AKESO's ivonescimab first-line biliary tract cancer Phase 3 HARMONi-GI1 study was selected for the highest-level Presidential Symposium, providing direct catalyst for this movement.

Multiple investment banks have recently highlighted that ESMO will bring intensive catalysts for the innovative drug sector. Chinese enterprises' LBA selections include four entries into the Presidential Symposium, indicating that China's innovative drug R&D capabilities are widely recognized overseas, and the innovative drug sector deserves continued attention.

Prior to this movement, AKESO had experienced two consecutive days of pullback due to profit-taking in the biotechnology sector, and this ESMO catalyst has reignited buying interest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hkg.itiger.com/news/1123515807"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123515807\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123515807?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-09 14:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123515807","market":"us","top_or_hot":-1,"title":"Movement Alert｜AKESO Rises 4.26% in Regular Trading, ESMO Conference Catalyzes Innovative Drug Valuation","media":"Market Focus","content":"<p><p>On October 9, AKESO rose 4.26% in regular trading, trading at HK$110.0/share, with Turnover of HK$892 million.</p><p>The ESMO 2026 Annual Meeting will be held from October 23 to 27. Chinese innovative drug research accounts for over 30% of Late-Breaking Abstracts (LBA), among which AKESO's ivonescimab first-line biliary tract cancer Phase 3 HARMONi-GI1 study was selected for the highest-level Presidential Symposium, providing direct catalyst for this movement.</p><p>Multiple investment banks have recently highlighted that ESMO will bring intensive catalysts for the innovative drug sector. Chinese enterprises' LBA selections include four entries into the Presidential Symposium, indicating that China's innovative drug R&D capabilities are widely recognized overseas, and the innovative drug sector deserves continued attention.</p><p>Prior to this movement, AKESO had experienced two consecutive days of pullback due to profit-taking in the biotechnology sector, and this ESMO catalyst has reignited buying interest.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Rises 4.26% in Regular Trading, ESMO Conference Catalyzes Innovative Drug Valuation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Rises 4.26% in Regular Trading, ESMO Conference Catalyzes Innovative Drug Valuation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-09 14:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 9, AKESO rose 4.26% in regular trading, trading at HK$110.0/share, with Turnover of HK$892 million.</p><p>The ESMO 2026 Annual Meeting will be held from October 23 to 27. Chinese innovative drug research accounts for over 30% of Late-Breaking Abstracts (LBA), among which AKESO's ivonescimab first-line biliary tract cancer Phase 3 HARMONi-GI1 study was selected for the highest-level Presidential Symposium, providing direct catalyst for this movement.</p><p>Multiple investment banks have recently highlighted that ESMO will bring intensive catalysts for the innovative drug sector. Chinese enterprises' LBA selections include four entries into the Presidential Symposium, indicating that China's innovative drug R&D capabilities are widely recognized overseas, and the innovative drug sector deserves continued attention.</p><p>Prior to this movement, AKESO had experienced two consecutive days of pullback due to profit-taking in the biotechnology sector, and this ESMO catalyst has reignited buying interest.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1123515807","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123515807","pubTimestamp":1791528254,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 9, AKESO rose 4.26% in regular trading, trading at HK$110.0/share, with Turnover of HK$892 million.The ESMO 2026 Annual Meeting will be held from October 23 to 27. Chinese innovative drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提醒|AKESO常规交易上涨4.26%，ESMO会议催化创新药估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On October 9, AKESO rose 4.26% in regular trading, trading at HK$110.0/share, with Turnover of HK$892 million.The ESMO 2026 Annual Meeting will be held from October 23 to 27. Chinese innovative drug research accounts for over 30% of Late-Breaking Abstracts (LBA), among which AKESO's ivonescimab first-line biliary tract cancer Phase 3 HARMONi-GI1 study was selected for the highest-level Presidential Symposium, providing direct catalyst for this movement.Multiple investment banks have recently highlighted that ESMO will bring intensive catalysts for the innovative drug sector. Chinese enterprises' LBA selections include four entries into the Presidential Symposium, indicating that China's innovative drug R&D capabilities are widely recognized overseas, and the innovative drug sector deserves continued attention.Prior to this movement, AKESO had experienced two consecutive days of pullback due to profit-taking in the biotechnology sector, and this ESMO catalyst has reignited buying interest.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}